文献速递主动脉疾病外周动脉疾病

AFX单体型支架移植物治疗TASC D主髂动脉病变合并腹主动脉瘤的结果

Results of AFX Unibody Stent-Graft Implantation in Patients With TASC D Aortoiliac Lesions and Coexistent Abdominal Aortic Aneurysms.
PubMed 文献 · J Endovasc Ther · 2017-09-11

该回顾性研究纳入21例TASC D主髂动脉闭塞性疾病合并腹主动脉瘤(直径>3.5 cm)患者,择期使用AFX单体型支架移植物治疗。技术成功率100%,30天无死亡或主要不良事件,平均随访25.2个月一期通畅率100%,ABI和Rutherford分级持续改善,提示AFX支架是安全有效的解决方案。

要点

  • AFX单体型支架治疗TASC D主髂动脉病变合并AAA技术成功率100%。
  • 30天无死亡或主要不良事件,平均随访25.2个月一期通畅率100%。
  • ABI和Rutherford分级在随访期间持续改善,无死亡或截肢。

核心结论

  • AFX单体型支架移植物对于TASC D主髂动脉闭塞性疾病合并腹主动脉瘤的复杂病变似乎是安全有效的解决方案,发病率和死亡率低。

研究设计与样本

  • 回顾性分析连续21例(平均年龄73.6±6.4岁,17例男性)TASC D主髂动脉闭塞性疾病合并腹主动脉瘤(直径>3.5 cm)择期使用AFX支架治疗的患者。

主要发现

  • AFX部署后技术成功率100%,18例外髂动脉需要辅助支架,髂总动脉无辅助支架。
  • 30天随访无死亡或主要不良事件,所有患者ABI改善(平均0.91±0.11),一期通畅率100%。
  • 平均随访25.2±11.1个月,一期通畅率维持100%,无死亡或截肢,2例发生心肌梗死。
  • ABI改善维持(0.88±0.13),Rutherford分级也维持改善。

临床怎么用

  • 对于TASC D主髂动脉闭塞性疾病合并腹主动脉瘤的患者,可考虑使用AFX单体型支架移植物进行择期治疗。
  • 术后需监测ABI和Rutherford分级以评估疗效,并关注心肌梗死等不良事件。

局限性

  • 回顾性研究,样本量较小(21例),随访时间有限(平均25.2个月)。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

PURPOSE: To describe results of AFX unibody stent-graft treatment for TransAtlantic Inter-Society Consensus (TASC) D aortoiliac occlusive disease (AIOD) with coexistent abdominal aortic aneurysm (AAA). METHODS: A retrospective analysis was conducted of 21 consecutive patients (mean age 73.6±6.4 years; 17 men) with TASC D AIOD plus AAA (diameter >3.5 cm) treated electively using the AFX stent-graft. Common iliac artery (CIA) and external iliac artery (EIA) stenosis or occlusion was reported. Outcome measures were technical and clinical success, improvement in ankle-brachial index (ABI), and improvement in Rutherford category. Immediate and midterm patency, AAA exclusion, major adverse events (MAE), and mortality were also evaluated. RESULTS: After AFX deployment (100% technical success), 18 EIAs required adjunctive stenting (none required in the CIA). One patient required a reintervention for closure device failure. At 30-day follow-up, no death or MAE was recorded. Improvement in ABI was registered in all patients (mean 0.91±0.11), with 100% primary patency. At a mean follow-up of 25.2±11.1 months, primary patency was maintained in all cases. No death or amputation occurred; 2 patients had a myocardial infarction. Improvement in ABI was maintained (0.88±0.13) as well as Rutherford category. CONCLUSION: This study examined the use of the AFX unibody stent-graft for the treatment of TASC D AIOD with concomitant AAA. The AFX stent-graft appears to be a safe and effective solution for these complex lesions, with low morbidity and mortality.

来源:J Endovasc Ther,查看原文。版权归原作者所有。

引用

  1. Sirignano P, Mansour W, Capoccia L, et al. Results of AFX Unibody Stent-Graft Implantation in Patients With TASC D Aortoiliac Lesions and Coexistent Abdominal Aortic Aneurysms. J Endovasc Ther. 2017. PMID: 28891375. doi:10.1177/1526602817730840

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。